JP2008539235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539235A5 JP2008539235A5 JP2008508931A JP2008508931A JP2008539235A5 JP 2008539235 A5 JP2008539235 A5 JP 2008539235A5 JP 2008508931 A JP2008508931 A JP 2008508931A JP 2008508931 A JP2008508931 A JP 2008508931A JP 2008539235 A5 JP2008539235 A5 JP 2008539235A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- protecting group
- group
- amino acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- -1 4-methyltrityl Chemical group 0.000 claims 15
- 125000006239 protecting group Chemical group 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical group [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 claims 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- CBEFMGJHEKAMNI-UHFFFAOYSA-N 9-oxofluorene-1-carboxylic acid Chemical group C12=CC=CC=C2C(=O)C2=C1C=CC=C2C(=O)O CBEFMGJHEKAMNI-UHFFFAOYSA-N 0.000 claims 1
- HTPXFGUCAUTOEL-UHFFFAOYSA-N 9h-fluorene-1-carboxylic acid Chemical compound C1C2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 HTPXFGUCAUTOEL-UHFFFAOYSA-N 0.000 claims 1
- DNVJGJUGFFYUPT-UHFFFAOYSA-N 9h-fluorene-9-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)C3=CC=CC=C3C2=C1 DNVJGJUGFFYUPT-UHFFFAOYSA-N 0.000 claims 1
- 101150092476 ABCA1 gene Proteins 0.000 claims 1
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 claims 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010061619 Deformity Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67643105P | 2005-04-29 | 2005-04-29 | |
| US69749505P | 2005-07-07 | 2005-07-07 | |
| PCT/US2006/014839 WO2006118805A2 (en) | 2005-04-29 | 2006-04-18 | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008539235A JP2008539235A (ja) | 2008-11-13 |
| JP2008539235A5 true JP2008539235A5 (enExample) | 2009-06-04 |
Family
ID=37308461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508931A Pending JP2008539235A (ja) | 2005-04-29 | 2006-04-18 | 炎症反応によって特徴付けられる病状を処置するためのペプチドおよびペプチド模倣物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100227825A1 (enExample) |
| EP (3) | EP2269623A1 (enExample) |
| JP (1) | JP2008539235A (enExample) |
| KR (1) | KR20080007491A (enExample) |
| AU (1) | AU2006242651B2 (enExample) |
| BR (1) | BRPI0610983A2 (enExample) |
| CA (1) | CA2607483A1 (enExample) |
| EA (2) | EA200900786A1 (enExample) |
| EC (1) | ECSP077829A (enExample) |
| IL (1) | IL186959A0 (enExample) |
| MA (1) | MA29488B1 (enExample) |
| MX (1) | MX2007013430A (enExample) |
| NO (1) | NO20076022L (enExample) |
| NZ (2) | NZ580954A (enExample) |
| SG (1) | SG173373A1 (enExample) |
| TN (1) | TNSN07396A1 (enExample) |
| WO (1) | WO2006118805A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| WO2012047930A2 (en) | 2010-10-04 | 2012-04-12 | The Regents Of The University Of California | Compositions and methods for treatment of gynecologic cancers |
| RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| EP2049137A4 (en) | 2006-08-08 | 2013-05-01 | Univ California | SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES |
| KR101461659B1 (ko) * | 2007-05-11 | 2014-11-17 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| AU2014200542B2 (en) * | 2007-05-11 | 2016-08-25 | Rowan University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| AU2008296478B9 (en) * | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| EP2240196A2 (en) | 2008-01-22 | 2010-10-20 | Compugen Ltd. | Clusterin derived peptide |
| WO2010020822A1 (en) * | 2008-08-19 | 2010-02-25 | University Of Patras | Therapy for apolipoprotein-induced hypertriglyceridemia |
| WO2010049103A1 (en) * | 2008-10-31 | 2010-05-06 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| WO2011040654A1 (ko) * | 2009-09-30 | 2011-04-07 | 서울대학교산학협력단 | 아포리포프로테인 에이１ 모방 펩타이드，및 이를 포함하는 고지혈증 및 이와 관련된 질환 치료제 |
| CN104039810A (zh) | 2011-08-29 | 2014-09-10 | 加利福尼亚大学董事会 | 使用高密度脂蛋白(hdl)相关分子治疗和预防促炎性病状 |
| US9539300B2 (en) | 2012-03-31 | 2017-01-10 | The Regents Of The University Of California | Modulating disease through genetic engineering of plants |
| KR102017026B1 (ko) * | 2013-01-10 | 2019-09-02 | (주) 수파드엘릭사 | 염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물 |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| US10987401B2 (en) * | 2015-05-01 | 2021-04-27 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics for treating ocular disorders |
| CN114621318A (zh) * | 2015-05-12 | 2022-06-14 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| US10905736B2 (en) | 2016-09-28 | 2021-02-02 | The Regents Of The University Of California | Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism |
| US10426817B2 (en) | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
| CN117777238A (zh) * | 2017-09-15 | 2024-03-29 | 凯恩塞恩斯株式会社 | 作为自身免疫疾病及骨病治疗剂的肽的用途 |
| GB2576705A (en) * | 2018-08-17 | 2020-03-04 | E Miller Norman | Improvements in or relating to organic material |
| CN111796098B (zh) * | 2020-05-29 | 2021-06-01 | 中国科学院武汉病毒研究所 | 诊断新冠肺炎由重症转危重症的血浆蛋白标志物、检测试剂或检测工具 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US651842A (en) * | 1899-08-18 | 1900-06-19 | James Thomas Ford | Friction-clutch. |
| US3767040A (en) | 1971-03-01 | 1973-10-23 | Minnesota Mining & Mfg | Pressure-sensitive polyurethane adhesives |
| US4155913A (en) * | 1973-02-08 | 1979-05-22 | Hoffmann-La Roche Inc. | Thienotriazolodiazepine derivatives |
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| HU185263B (en) * | 1981-06-12 | 1984-12-28 | Richter Gedeon Vegyeszet | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| CH661438A5 (it) * | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| US4643988A (en) | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US4969458A (en) | 1987-07-06 | 1990-11-13 | Medtronic, Inc. | Intracoronary stent and method of simultaneous angioplasty and stent implant |
| NZ229004A (en) * | 1988-05-19 | 1993-09-27 | Immunobiology Res Inst Inc | Tetrapeptides having t cell helper acitivity |
| US5480869A (en) * | 1990-01-09 | 1996-01-02 | The Regents Of The University Of California | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues |
| AU662885B2 (en) * | 1990-06-07 | 1995-09-21 | Scripps Research Institute, The | APO AI polypeptides, antibodies, and immunoassays |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| WO1993025581A1 (en) * | 1992-06-12 | 1993-12-23 | N.V. Innogenetics S.A. | New peptides and proteins, process for their preparation and their use as cholesterol acceptors |
| US5344822A (en) * | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
| WO1994004563A1 (fr) * | 1992-08-14 | 1994-03-03 | Shino-Test Corporation | PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS |
| US5358934A (en) * | 1992-12-11 | 1994-10-25 | The United States Of America As Represented By The Secretary Of Agriculture | Materials and methods for control of pests |
| US5721138A (en) * | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| US6773719B2 (en) | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| US5746223A (en) | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
| US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US5595973A (en) * | 1994-09-12 | 1997-01-21 | Biomeasure Incorporated | Protection of hemopoietic cells during chemotherapy or radiotherapy |
| US5639726A (en) | 1994-09-30 | 1997-06-17 | The Regents Of The University Of Michigan | Peptide mediated enhancement of thrombolysis methods and compositions |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US6717031B2 (en) * | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| CN1109047C (zh) | 1996-03-29 | 2003-05-21 | D·博菲利 | 作为胆固醇和其它脂类摄取抑制剂的两亲分子 |
| SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| WO2001032837A1 (en) * | 1999-11-02 | 2001-05-10 | Human Genome Sciences, Inc. | 19 human secreted proteins |
| EP1003501B9 (en) * | 1997-04-02 | 2005-06-08 | The Brigham And Women's Hospital, Inc. | Use of an agent for lowering the risk of cardiovascular disease |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| DE69805697T3 (de) * | 1997-04-24 | 2006-11-30 | Chemoxal S.A. | Desinfizierende und fungizide Zusammensetzung auf der Basis von Peressigsäure und einem Aminoxid |
| US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6191151B1 (en) * | 1997-11-12 | 2001-02-20 | Howard M. Zik | Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers |
| US20030077641A1 (en) * | 1998-03-11 | 2003-04-24 | Laskowitz Daniel T. | Methods of suppressing microglial activation and systemic inflammatory responses |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| US6846636B1 (en) * | 1998-05-15 | 2005-01-25 | American National Red Cross | Methods and compositions for HDL holoparticle uptake receptor |
| US6019739A (en) * | 1998-06-18 | 2000-02-01 | Baxter International Inc. | Minimally invasive valve annulus sizer |
| US6228989B1 (en) * | 1998-11-13 | 2001-05-08 | The Regents Of The University Of California | Peptide substrates phosphorylated by P21-activated protein kinase |
| WO2000034469A1 (en) * | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| CN1329359C (zh) | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
| US6887470B1 (en) * | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| GB9911689D0 (en) * | 1999-05-19 | 1999-07-21 | Medical Res Council | Refolding method |
| US6727063B1 (en) * | 1999-09-10 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Single nucleotide polymorphisms in genes |
| JP2001299364A (ja) * | 1999-12-27 | 2001-10-30 | Takeda Chem Ind Ltd | 新規タンパク質およびそのｄｎａ |
| US20030040505A1 (en) | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US6596544B1 (en) | 2000-03-31 | 2003-07-22 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| US6444681B1 (en) * | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| US6680203B2 (en) | 2000-07-10 | 2004-01-20 | Esperion Therapeutics, Inc. | Fourier transform mass spectrometry of complex biological samples |
| WO2002008188A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7166578B2 (en) * | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| CN1283610C (zh) | 2000-10-11 | 2006-11-08 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
| JP2004532799A (ja) | 2000-10-11 | 2004-10-28 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物 |
| JP2004531459A (ja) | 2000-10-11 | 2004-10-14 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用 |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| US20040122091A1 (en) | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| WO2002059077A1 (en) * | 2001-01-26 | 2002-08-01 | Takeda Chemical Industries, Ltd. | Aminoethanol derivatives |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| US6815426B2 (en) * | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| US7217785B2 (en) * | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| CA2460787A1 (en) | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| US20030125260A1 (en) * | 2001-10-31 | 2003-07-03 | Fortuna Haviv | Tetra-and pentapeptides having antiangiogenic activity |
| US7308303B2 (en) * | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| AU2003202737A1 (en) * | 2002-02-28 | 2003-09-09 | Koninklijke Philips Electronics N.V. | Method for controlling the mode of an electronic application |
| US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| CN101745112A (zh) * | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| JP2004067583A (ja) * | 2002-08-06 | 2004-03-04 | Sumitomo Pharmaceut Co Ltd | 新規ペプチド誘導体 |
| AU2003291206A1 (en) * | 2002-12-04 | 2004-06-23 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| WO2004069206A2 (en) * | 2003-02-04 | 2004-08-19 | University Of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| US8088404B2 (en) | 2003-03-20 | 2012-01-03 | Medtronic Vasular, Inc. | Biocompatible controlled release coatings for medical devices and related methods |
| US20050070996A1 (en) | 2003-04-08 | 2005-03-31 | Dinh Thomas Q. | Drug-eluting stent for controlled drug delivery |
| US7291590B2 (en) * | 2003-06-12 | 2007-11-06 | Queen's University At Kingston | Compositions and methods for treating atherosclerosis |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| US7781219B2 (en) * | 2003-12-05 | 2010-08-24 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| RU2414236C2 (ru) * | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
-
2006
- 2006-04-18 EA EA200900786A patent/EA200900786A1/ru unknown
- 2006-04-18 AU AU2006242651A patent/AU2006242651B2/en not_active Ceased
- 2006-04-18 NZ NZ580954A patent/NZ580954A/en not_active IP Right Cessation
- 2006-04-18 EP EP10177858A patent/EP2269623A1/en not_active Withdrawn
- 2006-04-18 JP JP2008508931A patent/JP2008539235A/ja active Pending
- 2006-04-18 CA CA002607483A patent/CA2607483A1/en not_active Abandoned
- 2006-04-18 MX MX2007013430A patent/MX2007013430A/es active IP Right Grant
- 2006-04-18 SG SG2011051224A patent/SG173373A1/en unknown
- 2006-04-18 EA EA200702392A patent/EA012440B1/ru not_active IP Right Cessation
- 2006-04-18 KR KR1020077027948A patent/KR20080007491A/ko not_active Ceased
- 2006-04-18 EP EP06750791A patent/EP1890715A4/en not_active Withdrawn
- 2006-04-18 EP EP11155927.4A patent/EP2368561B1/en active Active
- 2006-04-18 WO PCT/US2006/014839 patent/WO2006118805A2/en not_active Ceased
- 2006-04-18 BR BRPI0610983-7A patent/BRPI0610983A2/pt not_active Application Discontinuation
- 2006-04-18 NZ NZ563187A patent/NZ563187A/en not_active IP Right Cessation
-
2007
- 2007-10-24 TN TNP2007000396A patent/TNSN07396A1/en unknown
- 2007-10-26 EC EC2007007829A patent/ECSP077829A/es unknown
- 2007-10-28 IL IL186959A patent/IL186959A0/en unknown
- 2007-11-22 NO NO20076022A patent/NO20076022L/no not_active Application Discontinuation
- 2007-11-27 MA MA30425A patent/MA29488B1/fr unknown
-
2010
- 2010-03-10 US US12/721,366 patent/US20100227825A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539235A5 (enExample) | ||
| JP2008522980A5 (enExample) | ||
| JP2017530090A5 (enExample) | ||
| CA2718348A1 (en) | Orally administered peptides to ameliorate atherosclerosis | |
| PE20231841A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| JP2012512903A5 (enExample) | ||
| TWI221845B (en) | Peptide analogues | |
| AU2006207659B2 (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
| JP2013515057A5 (enExample) | ||
| JP2008506709A5 (enExample) | ||
| JP2008539713A5 (enExample) | ||
| US20060211610A1 (en) | Peptide yy analogs | |
| PE20231842A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| RU2008100238A (ru) | Соединения оксинтомодулина, фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) | |
| JP2011515449A5 (enExample) | ||
| MX2022011834A (es) | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. | |
| WO2012014214A2 (en) | Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension | |
| US20220041680A1 (en) | Process for the manufacture of glp-1 analogues | |
| CN115677827A (zh) | 肽化合物 | |
| Hong et al. | Synthesis and biological studies of novel neurotensin (8–13) mimetics | |
| JP5421257B2 (ja) | プラスミノーゲン活性化因子阻害物質１由来のペプチドおよびその使用 | |
| WO2010058419A4 (en) | Tumor necrosis factor alpha inhibiting peptides and uses thereof | |
| JP2009542235A5 (enExample) | ||
| PE20081000A1 (es) | Nuevos analogos del peptido intestinal vasoactivo | |
| NZ597777A (en) | Motilin-like peptide compound having transmucosal absorbability imparted thereto |